Associate Director, Investor Relations & Corporate Communications
Alnylam Pharmaceuticals, Inc.
Joshua Brodsky is Associate Director, Investor Relations & Corporate Communications at Alnylam Pharmaceuticals (NASDAQ:ALNY), a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. At Alnylam, Josh is involved with developing, implementing, and expanding the company’s IR strategy, as well as nurturing existing and building new relationships with key stakeholders on the buy-side and sell-side. He also assists in the management of an active newsflow engine in support of Alnylam’s overall external communications.
Prior to joining Alnylam’s Investor Relations & Corporate Communications group in 2012, Josh spent six years working in the company’s scientific organization, where he contributed to the advancement of multiple programs in a variety of therapeutic areas. Before joining Alnylam in 2006, Josh spent three years as a Research Associate in the Women’s and Perinatal Pathology Department at Brigham and Women’s Hospital.
Josh received his MBA from the Boston University Graduate School of Management (now the Boston University Questrom School of Business) and his Bachelor of Science in Neuroscience with a Minor in Music from Lafayette College.